Why is Tenax Therapeutics stock collapsing today?
Tenax Therapeutics (TENX) shares fell about 84% pre-open after its Phase 3 LEVEL trial of TNX-103 (oral levosimendan) failed to meet the primary endpoint for pulmonary hypertension due to heart failure with preserved ejection fraction, with a 3.5-meter least-squares mean difference and p-value 0.63. It also missed a key secondary endpoint. The company is evaluating next steps and has $118 million cash runway through mid-2028.
How this was made
The 30-second read
Why it matters
The disclosed Phase 3 LEVEL failure (primary endpoint miss and key secondary miss) is a direct probability reset for regulatory approval and increases the likelihood of dilution or strategic restructuring if LEVEL-2 does not recover the story.
Market read
A late-stage clinical binary miss drives an immediate repricing of TNX-103’s regulatory odds and the company’s funding and development path.
What to watch
The article notes the $118M cash runway through mid-2028; traders may need to watch for how management plans to use LEVEL-2 results to justify additional capital or partnerships.
Background
Tenax Therapeutics is pre-revenue and cash-burning, with TNX-103 in late-stage development for pulmonary hypertension due to heart failure with preserved ejection fraction.
Ticker impact
Tenax Therapeutics shares plunged 84.2% pre-open after its Phase 3 LEVEL trial of TNX-103 failed the primary endpoint (p=0.63).
Further downside pressure likely as investors reprice the probability of success for LEVEL-2 and the adequacy of the $118M cash runway.
The article discloses a binary clinical readout miss (primary and key secondary endpoints) plus a pre-revenue, cash-burning profile, which typically drives immediate de-risking and valuation compression.
Market effects
Highlights heightened binary-risk for pulmonary hypertension drug development and can pressure sentiment toward similar pre-revenue biotech trial readouts.
Primarily US small-cap biotech sentiment; no clear macro driver cited.
Limited direct global spillover beyond biotech risk appetite for trial-stage cardiovascular assets.
Counterpoint
Subgroup analyses showed benefit in higher disease-burden patients and TNX-103 was generally safe, which could support a revised strategy for LEVEL-2 or future trial design.
Key entities
- companyTenax Therapeutics
Subject of the article; TNX-103 Phase 3 LEVEL trial failed primary and key secondary endpoints.
- drug_programTNX-103 (oral levosimendan)
Investigational therapy whose Phase 3 LEVEL results missed endpoints.
- clinical_trialLEVEL-2
Ongoing global Phase 3 trial that becomes the next focal catalyst after LEVEL failure.
